Dental Pulp Stem Cells for Tissue Engineered Heart Valve

DOI: 10.18805/ijar.B-1224    | Article Id: B-1224 | Page : 1554-1557
Citation :- Dental Pulp Stem Cells for Tissue Engineered Heart Valve.Indian Journal Of Animal Research.2020.(54):1554-1557
Soontaree Petchdee, Wilairat Chumsing, Suruk Udomsom, Kittiya Thunsiri
fvetstr@ku.ac.th
Address : Department of Large Animal and Wildlife Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, Kamphaeng Saen Nakorn Pathom 73140, Thailand.
Submitted Date : 18-11-2019
Accepted Date : 11-01-2020

Abstract

Myxomatous mitral valve degeneration is the most acquired heart disease in dogs. To reduce the clinical progression of mitral valve degeneration and achieve the hemodynamic outcomes, many medical or surgical treatments have been motivated. The objectives of this study is to investigate the suitability of puppy deciduous teeth stem cells as a cell source for tissue engineered heart valves in dog with degenerative valve disease. Puppy deciduous teeth stem cells (pDSCs) were seeded on the scaffolds which made from polylactic acid (PLA), polycaprolactone (PLC) and silicone. The mechanical properties of the tissue engineered heart valves leaflets were characterized by biaxial tensile tests. Results showed that, deciduous teeth stem cells capable of differentiating into a variety of cell types. However, the ability of puppy deciduous teeth stem cells to differentiate declined with increasing passage number which correspond to the number of protein surface marker detection have been shown to decrease substantially by the fifth passage. PLA scaffold is significantly higher tensile strength than other materials. However, silicone showed the highest flaccidity. The results from this study may provide high regenerative capability and the essential information for future directions of heart valve tissue engineering.

Keywords

Dental pulp stem cells Heart valve Tissue engineering

References

  1. Borgarelli, M., Haggstrom, J. (2010). Canine Degenerative Myxomatous Mitral Valve Disease: Natural History, Clinical Presentation and Therapy. Vet Clin Small Anim. 40: 651–663.
  2. Fuchs, S., Kornowski, R., Weisz, G. (2006). Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. AJC. 97: 823-829.
  3. Gandolfi, F., Vanelli, A., Pennarossa, G., Rahaman, M., Acocella, F., Brevini, T.A. (2011). Large animal models for cardiac stem cell therapies. Theriogenology. 75(8): 1416–1425. 
  4. Gepstein, L., Ding, C., Rahmutula, D., Wilson, E.E., Yankelson, L., Caspi, O., Olgin, J.E. (2010). In vivo assessment of the electrophysiological integration and arrhythmogenic risk of myocardial cell transplantation strategies. Stem Cells. 28(12): 2151–2161.
  5. Huang, G.T. J., Gronthos, S., Shi, S. (2009). Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. JDR. 88: 792-806.
  6. Indhu, M.S., Sesh, P.S.L., Loganathasamy, K., Jeyaraja, K., Padmanath, K., Pandiyan, V. (2019). Analysis of certain blood biochemical parameters in relation to oxidative stress in chronic mitral valve insufficiency of dogs with heart failure. Indian J. Anim. Res. 53(9): 1181-1187.
  7. Kumar, P., Yadav, A.K., Singh, V.K., Vandre, R.K., Singh, P.K., Verma, N., Das, R., Vineeth, M.R. (2015). Transgenic animal technology: Recent advances and applications: A Review. Agri. Review. 36(1): 46-53.
  8. Langer, R., Vacanti, J.P. (1993). Tissue engineering. Science. 260: 920-926.
  9. Malafaya, P.B., Silva, G.A., Reis, R.L. (2007). Natural origin polymers as carriers and scaolds for biomolecules and cell delivery in tissue engineering applications. Adv. Drug Deliv. Rev. 59: 207–233. 
  10. Meirelles, L., Da, S. and Nardi, N.B. (2003). Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion and characterization. BJH. 123: 702–711.
  11. Nair, L.S., Laurencin, C.T. (2007). Biodegradable polymers as biomaterials. Prog. Polym. Sci. 32: 762–798.
  12. Petersen, T. and Niklason, L. (2007). Cellular lifespan and regenerative medicine. Biomaterials. 28: 3751-3756.
  13. Pina, S.; Ferreira, J. (2012). Bioresorbable Plates and Screws for Clinical Applications: A Review. J. Healthc. Eng. 3: 243–260. 
  14. Pina, S., Ribeiro, V.P., Marques, C.F., Maia, F. R., Silva, T. H. Reis, R.L., Oliveira. J.M. (2019). Scafolding strategies for tissue engineering and regenerative medicine applications. Materials. 1824: 1-42. 
  15. Scipio, F., Sprio, A., Folino, A., Cerere, E.M., Salamone, P., Yang, Z., Berrone, M., Prat, M., Losano, G., Rastaldo R., Berta, G.N. (2014). Cardiomyocytes promote dental pulp mesenchymal stem cell homing. Biochimica et Biophysica Acta. 1840: 2152-2161.
  16. Sesh, P.S.L., Venkatesan, P., Jeyaraja, K., Chandrasekar, M. and Pandiyan,V. (2015). Xanthine oxidase as a biochemical marker of dilated cardiomyopathy in dogs. Indian J. Anim. Res. 49(2): 187-190.
  17. Shinoka, T., Matsumura, G., Hibino, N., Naito, Y., Watanabe, M., Konuma , T., Sakamoto, Stern, J.A., Hsue, W., Song, K.H., Ontiveros, E.S., Luis, F.V., Stepien, R.L. (2015). Severity of Mitral Valve Degeneration Is Associated with Chromosome 15 Loci in Whippet Dogs. PLoS One. 10(10):1-10.
  18. Shin’oka, T., Matsumura, G., Hibino, N., Naito, Y., Watanabe, M., Konuma, T., Sakamoto, T., Nagatsu, M,, Kurosawa, H. (2005). Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg. 129: 1330–1338.
  19. Tarnow, I., Olsen, L. H., Kvart, C., Hoglund, K., Moesgaarda, S.G., Kamstrupa, T.S., Pedersenc, H.D., Haggstro, J. (2009). Predictive value of natriuretic peptides in dogs with mitral valve disease. The Veterinary Journal. 180: 195–201. 

Global Footprints